Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Chabala
John C. Chabala, Mountainside, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20100063073 | Methods and Compositions Utilizing Quinazolinones - Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity. | 03-11-2010 |
| 20100210670 | METHODS AND COMPOSTIONS UTILIZIING QUINAZOLINONES - Quinazolinones of formulae (a, b, c and d) are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity. | 08-19-2010 |
John C. Chabala, Scotch Plains, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20110190237 | Macrocyclic Prodrug Compounds Useful as Therapeutics - The present invention includes macrocyclic prodrug compounds, pharmaceutical compositions containing them. The present invention also includes use of these compounds in the treatment of various diseases including an autoimmune disease, an inflammatory disease, a neurological or neurodegenerative disease, cancer, a cardiovascular disease, allergy, asthma, a hormone-related disease, and tumors or symptoms resulting from neurofibromatosis. | 08-04-2011 |
John Clifford Chabala, Scotch Plains, NJ US
John Clifford Chabala, Mountainside, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20080200398 | Compounds For Enzyme Inhibition - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. | 08-21-2008 |